InvestorsObserver
×
News Home

What is the Market's View on Otonomy Inc (OTIC) Stock's Price and Volume Trends Tuesday?

Tuesday, December 20, 2022 01:39 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Otonomy Inc (OTIC) Stock's Price and Volume Trends Tuesday?

Otonomy Inc (OTIC) stock is down 16.67% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,neutral
Otonomy Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on OTIC!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With OTIC Stock Today?

Otonomy Inc (OTIC) stock is lower by -14.82% while the S&P 500 is higher by 0.45% as of 1:38 PM on Tuesday, Dec 20. OTIC has fallen -$0.02 from the previous closing price of $0.11 on volume of 18,567,401 shares. Over the past year the S&P 500 is down -16.05% while OTIC has fallen -95.35%. OTIC lost -$0.77 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Otonomy Inc click here.

More About Otonomy Inc

Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States. Click Here to get the full Stock Report for Otonomy Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App